Compositions and methods for diagnosis and treatment of prostate cancer
AssigneeNovartis AG
InventorsZineb MOUNIR, Raymond PAL PAGLIARINI
Life of this patent
Estimating the term…
Abstract
The invention provides novel personalized therapies, kits, transmittable forms of information and methods for use in treating subjects having TMPRSS2:ERG positive prostate cancer, which we show is amenable to therapeutic treatment with a PRMT5 inhibitor. Kits, methods of screening for candidate PRMT5 inhibitors, and associated methods of treatment are also provided.
Claims31
A method for inhibiting the proliferation of TMPRSS2:ERG positive prostate cancer cells in a subject in need thereof, the method comprising the step of administering to the subject a PRMT5 inhibitor in an amount that is effective to inhibit the proliferation of the TMPRSS2:ERG positive prostate cancer cells.
A method of determining if a subject afflicted with prostate cancer will respond to therapeutic treatment with a PRMT5 inhibitor, comprising the steps of:
- (a) evaluating a test sample obtained from said subject for TMPRSS2:ERG positivity, wherein TMPRSS2:ERG positivity indicates that the subject will respond to therapeutic treatment with a PRMT5 inhibitor;
- wherein the method comprises any one or more of the following optional steps:
- (b) determining the level and/or activity of PRMT5 in the subject, wherein steps a) and b) can be performed in any order;
- (c) administering a therapeutically effective amount of a PRMT5 inhibitor to the subject;
- and
- (d) determining the level and/or activity of PRMT5 in the subject following step c), wherein a decrease in the level and/or activity of PRMT5 is correlated with the inhibition of the proliferation of the cancer, and wherein steps c) and d) are performed after steps a) and b).
A method of determining if a subject afflicted with prostate cancer will respond to therapeutic treatment with a PRMT5 inhibitor, comprising the steps of:
- (a) evaluating a test sample obtained from said subject for methylation of R761 of Androgen Receptor, wherein methylation of R761 of Androgen Receptor indicates that the subject will respond to therapeutic treatment with a PRMT5 inhibitor;
- wherein the method comprises any one or more of the following optional steps:
- (b) determining the level and/or activity of PRMT5 in the subject, wherein steps a) and b) can be performed in any order;
- (c) administering a therapeutically effective amount of a PRMT5 inhibitor to the subject;
- and
- (d) determining the level and/or activity of PRMT5 in the subject following step c), wherein a decrease in the level and/or activity of PRMT5 is correlated with the inhibition of the proliferation of the cancer, and wherein steps c) and d) are performed after steps a) and b).
-45. (canceled)
(canceled)
Dependencies are inferred from the claim text.